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1. Introduction 
The purpose of this review letter is to summarize 
recent attempts to label and isolate membrane pro- 
teins, in particular, substrate transporters, and also 
several drug receptors and enzymes. It is assumed that 
the transport or receptor system has already been stu- 
died with respect to substrate specificity, inhibitors, 
kinetics etc., before efforts are begun to isolate the 
proteins involved in the activity. Attempts to isolate 
these specific proteins may be divided into two types: 
1) The protein is specifically labelled in situ, solu- 
bilized, and then purified. 
2) Alternatively, the membrane is solubilized, and 
the protein identified and purified subsequently. 
2. In situ labelling 2.1. The pgalactoside perrnease in E. coli 
The theoretical and practical aspects of active site 
labelling of purified soluble proteins have been dis- 
cussed [l-3] . One major point to be emphasized here 
Abbreviations: 
ACh : acetylcholine 
ADP : adenosine diphosphate 
ATP : adenosine triphosphate 
ATPase : adenosine triphosphatase 
Carb : carbamylcholine 
DFP : diisopropylfluorophosphate 
DNP-Lys: e-A’-(2,4dinitrophenyl)-lysine 
FDNB : fluoro-2,4dinitrobenzene 
NEM : N-ethyhnaleimide 
SDS : sodium dodecyl sulfate 
The Roman numerals refer to the compounds in tables l-4. 
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is that the criteria for site specificity have been satis- 
fied to varying degrees for a number of different 
enzymes, but in most cases there is no direct evidence 
that labelling has occurred exclusively at the presumed 
site. The second point is that a particular membrane 
transporter or receptor will probably account for 
less than 1% of the total cellular protein. Therefore, 
it is especially relevant to note that specific labelling 
of a single protein has yet to be demonstrated when 
this protein is a minor component of a mixture. 
Tables I,2 and 3 list the types of membrane sys- 
tems in which labelling has been attempted with 
either specific or non-specific covalently-bound inhi- 
bitors. Several of these are discussed in the text, fol- 
lowed by some general comments on in situ labelling 
of membrane proteins. 
This permease (M protein) was identified by using 
a double-labelling technique, with 3H- and 14C-NEM 
(I), which involved substrate protection of uninduced 
and induced cells, and control studies with mutant 
strains lacking permease activity [4] . The usual non- 
metabolizable transport substrate, methyl-1-thio$ 
Dgalactoside (II), did not protect the active sites 
from being labelled, whereas /3-D-galactopyranosyl- I- 
thi@-D-galactoside protected these sites and caused 
a 2.5 fold decrease in incorporated tritium counts, 
suggesting the presence of at least two classes of 
sugar binding sites on the M protein [5,6] . The mem- 
brane was solubilized with Triton X-100 or with SDS, 
and the labelled fraction contained five major and 
numerous minor protein bands; 5% of the radio- 
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A ffinity labelling of membrane transporters. 
Transport system 
Lactose permease 
Escherichia coli 
Dicarboxylate 
transporter, rat 
liver mitochondri; 
Adenine nucleo- 
tide transporter, 
rat liver mito- 
chondria 
Glucose trans- 
porter, human 
red cells 
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Labelling reagent 
“X 
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a4 R=a-I& 
Comments 
See text. 
N-(4-Acetoxymercuri)-3- 
methoxybutyryl-l-fucosyl- 
amine (III) inhibited sugar 
uptake at 10e3 M. 
N-Bromoacetyl-a-lactosyl- 
amine (IV) inhibited at 10e4 
M. Nature of inhibition not 
known. 
See text 
Atractyligenin is a competi- 
tive inhibitor of ADP (X) trans- 
location, but not known whether 
inhibitor and substrate react at 
same sites. Epoxide (XI) is com- 
petitive inhibitor at 2.5 X 10m4 
M. C15-OH and Cl6-methylene 
groups of atractyligenin not essen- 
tial for activitv. 
Inhibition by FDNB known to 
be dependent upon square of 
inhibitor concentration. One 
aliquot of cells incubated with 
1 mM FDNB for 10 min, and 2nd 
aliquot with 10 mM FDNB for 1 
min, upon assumption that 2nd 
ahquot would be preferentially la- 
belled at carrier site. Total of 3 X II 
DNP residues (4.5 nmoles DNP re- 
sidues per ml packed cells), though 
to be specific for carrier; isolated 
mainly as derivative of cysteine, ph 
small amounts of lysine and histidit 
No direct proof that carrier was lab 
t 
1S 
ne. 
elled 
<efs - 
1 
8 
11 
- 
II 
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Transport system 
Monosaccharide 
transporter, 
rabbit red cell 
Substrate Labelling reagent 
*H 
cutl 
Comments 
Substrate analogue (XII) and 
competitive inhibitor (XIII) 
failed to inhibit xylose trans- 
port. 
Refs 
16.17 
activity was located in one band, which did not 
correspond to any of the major protein bands [7]. 
Some of the labelling reagent was recovered as S- 
succinyl-cysteine, confirming that the reactive resi- 
due in the M protein was a cysteine. The molecular 
weight of the major labelled band was between 
29,000 and 3 1,000 daltons and contained no phos- 
pholipid. In fully induced cells, the M protein re- 
presented between 2-4% of the protein in the par- 
ticulate fractions, and about 0.35% of the total pro- 
tein [13]. 
Another approach to labelling the lac permease 
involved the use of a number of derivatives of 
D-glucopyranosylamine, D-galactopyranosylamine, 
Lfucosylamine and a-lactosylamine [8]. The N- 
4-acetoxymercuri-3-methoxybutyryl derivatives (III) 
of the first three of these gave 100% inhibition of 
sugar uptake at 10d4 M, whilst N-bromoacetyl-o- 
lactosylamine (IV) gave 100% inhibition at 10e3 M. 
No further data are available at the present time. 
Stein and his colleagues [9] attempted to label 
the fat permease not with an inhibitor but by com- 
paring the incorporation into protein of phenylalanine 
in induced and uninduced populations, using 14C and 
3H isotopes respectively [lo] . Enrichment of a pro- 
tein in 14C over 3H, indicating that the protein may 
be a product of the lac operon, was found in fractions 
corresponding to P-galactoside transacetylase and p- 
galactosidase, as well as two other fractions. One of 
the latter fractions was membrane bound, had a mole- 
cular weight of 30,000-40,000 daltons and accounted 
for 12% of the protein. It may correspond, in part, to 
the M protein. The fouth labelled fraction was cyto- 
plasmic (soluble), had a low molecular weight, and 
may represent either a biosynthetic precursor or a 
degradation product of the operon. This most inter- 
esting approach requires an inducible transporter and, 
therefore, cannot be used for the majority of mamma- 
lian membrane systems. 
2.2. Dicarboxylate transport system in rat liver mite- 
chondria 
We have used substrate analogues which are non- 
penetrating competitive inhibitors. The non-penetra- 
bility restricted by about 80% the amount of protein 
with which the labelling reagent could interact. Phthal- 
ate and 2-phenylsuccinate specifically inhibited the 
dicarboxylate porter with inhibitory constants (Ki) 
of about 1 X 10m3 M and 2 X 10m4 M, respectively 
1111. 
We have synthesized several affinity-labelling sub- 
strate analogues: p-bromoacetamidophenylsuccinate 
(V), p-iodoacetamidophenylsuccinate (VI), 4-bromo- 
acetamidophthalate (VII) and 4-iodoacetamidophthal- 
ate (VIII). When these compounds were tested at 
high concentrations and immediately after addition 
to the mitochondria, they were as good competitive 
inhibitors as were their parent compounds. However, 
they proved to be relatively slow alkylating reagents, 
requiring from 6 to 24 hr of incubation for signifi- 
cant irreversible effects. The amount of inhibition 
was variable, and usually there were effects upon other 
transport systems and other mitochondrial functions 
[ 1 I]. Furthermore, iodoacetate itself occasionally 
gave comparable effects. The more reactive N-diazo 
salts derived from 3- and 4-aminophthalate (IX) gave 
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Receptor 
system 
ATPase, Na, 
K-stimulated 
ouabain inhi- 
bited, brain 
microsomes 
Acetylcholine 
receptor, electro- 
plax excitable 
membrane 
Noradrenaline 
a-receptor, 
rat vas deferens 
‘hysiological igand 
&@ OH 
aw 
,$d, 
cub 
Nor- 
Table 2 
Affinity labelling of membrane receptors. 
Labelling reagent 
I- 
I- 
Comments 
Enzyme already solu- 
bilized with lubrol and 
purified 25 fold before 
labelling. Little or no in- 
hibition with bromoacetate 
analogue until 5 X lo4 M, 
and then rapid increase in 
inhibition up to 100% at 1 O-’ 
M. Substrate protection 
difficult to assess. Much non- 
specific labelling. 
Very narrow effective 
concentration range, 
between lo4 and 10e3 M. 
Very short incubation time, 
Reversed by incubation of 
tissue with 10m2 M histi- 
dine for 19 hr. 
Requires prior reduction 
of disulphide bond. 
See text. 
Much non-specific 
labelling. See text. 
Cholinethiol = 2-mer- 
captoethyltrimethyl- 
ammonium iodide (XXI), 
and bis-cholinethiol 
(XXII) cause several 
thousand fold increase in 
rate of recovery following 
treatment of tissue with 
dithiothreitol. 
Reactive species is ethyl- 
eniminium ion. Large 
amount of non-specific 
uptake by tissues, appar- 
ently unrelated to cy-recep- 
tors; no decrease in uptake 
by prior incubation with 
protective reagents. 
:efs. 
8, 19 
8, 29 
10 
11, 32 
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Receptor 
system 
Estrogen recep- 
tor, rat uterus 
Antigen recep- 
tor on antibody- 
synthesizing celh 
mouse spleen 
Physiological igand 
Table 2 (continued) 
Labelling reagent 
almost complete inhibition of osmotic swelling with- 
in 15-30 min and at concentrations about 100-fold 
lower than the haloacetamido compounds, but they 
too affected other mitochondrial activities. In addi- 
tion, similar effects were shown by N-diazo-p-amino- 
benzoate, although the p-aminobenzoate itself caused 
only slight competitive inhibition at concentrations 
100 fold higher. 
2.3. Adenine nucleotide transport system 
We have synthesized epoxybromo-atractyligenin 
(XI) which is as good a competitive inhibitor of ADP 
(X) transport as atractyligenin itself. The epoxide 
Comments 
Mercurial analogue com- 
petes for estrogen bind- 
ing sites on tissues as 
well as on proteins such 
as egg albumin, glutamate 
dehydrogenase, and pyru- 
vate kinase. 2-Diazoestrone 
sulfate (XXVI) studied 
only with soluble proteins. 
Mercurial (XXV) is bound 
non-covalently, and may 
therefore migrate during 
isolation procedures. 
4-Hydroxy-3-iodo-5-nitro- 
phenylacetic acid = NIP 
(XXVII). 4-Hydroxy-3- 
iodo&nitrophenacetyl 
azide = NIP azide (XXVIII) 
specifically inhibits anti- 
body synthesis to NIP at 
7 X 10d M, but at 10e4 
M, responses are inhibited 
to other antigens as well as 
to NIP. 
a-N-Bromacetyl-e-N- 
(2,4dinitrophenyl)- 
lysine = BADL (XXX) 
has significant inhibitory 
effects upon response to 
DNP-Lys (XXIX) at 
5 X 10” M. Also inhi- 
bits rabbit anti-DNP 
antibodies. 
Zefs. 
13-35 
36 
37 
ring is accessible and therefore is a potential nucleo- 
phile, but in preliminary experiments the compound 
has not been a satisfactory affinity label [ 111. 
2.4. Sugar transporters inred cells 
A unique method was used inan attempt to label 
the glucose transporter in human red cells. Langdon 
and Sloan [ 121 proposed that the sugar carbonyl 
formed a Schiff base (imine) with carrier amino 
groups and they attempted to trap this imine by re- 
duction with NaBH4. Incorporation of 14C-glucose 
was demonstrated with intact red cells, red cell 
ghosts and adipose cells, 50% of the 14C being located 
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in one protein fraction. Label could also be trapped 
in certain proteins, including hemoglobin, but with 
kinetics which were different from that in cells. 
LeFevre [ 131 detected errors in the original kinetic 
analyses and also reported unpublished experiments 
with 1 ,5-anhydro-D-glucitol, which lacks a carbonyl 
function but has a very high affinity for the carrier. 
Further investigations showed that the C-l carbonyl 
group was not incorporated in a Schiff base to any 
significant extent, and that the original results were 
probably not related to a major pathway for glucose 
transport [ 141 . 
Cooper et al. [ 161 have recently tried to label 
the monosaccharide transporter from rabbit red cells. 
6-Bromo-deoxyconduritol-/3-epoxide (XII), which 
had previously been used by Legler [ 171 to label the 
active centre of &$rcosidases A and B, had no inhi- 
bitory activity in the transport assay, and in fact 
caused a 15% increase in xylose uptake. Stilboestrol 
and hexoestrol, at 10d4 M, competitively inhibit 
xylose transport to the levels of 50 and 60%, respec- 
tively. Cooper et al. [ 161 prepared 3,3’-dibromo- 
acetamidohexoestrol (XIII), but this potential alky- 
lating reagent caused no significant reversible or 
irreversible inhibition. 
brain microsomes 
2.5. Ouabain-sensitive Na,K-dependent A TPase from 
A solubilized enzyme preparation was studied 
with a variety of inhibitors derived from strophan- 
thidin (XIV). Strophanthidin-3-bromoacetate (XV) 
caused irreversible inhibition when high concentra- 
tions ( 10e3 M) and prolonged incubation were used 
[ 181. Bromoacetate itself gave little inhibition under 
these conditions. A much larger number of strophan- 
thidin molecules were taken up by the enzyme pre- 
paration than the number of enzyme active sites as 
estimated from the amount of glutamyl-y-phosphate 
(a known intermediate for this reaction). Ninety 
percent of the non-specific labelling could be elimi- 
nated by prior incubation with non-analogue halo- 
acetate compounds whilst competitive substrate 
analogues had no protective effects. This work is 
presently being extended using a more potent inhi- 
bitor, hellebrigenin-3-iodoacetate (XVI) [ 191 . 
2.6. Acetylcholine receptor 
A great deal of information is availab!e about 
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this complex system in the electroplax electric organ, 
but for the present purposes, it is sufficient to note 
that several classes of ACh receptor sites can be 
distinguished functionally from the esterase site of 
acetylcholinesterase, and from the acetylcholine- 
triggered ‘ionophore’ responsible for ion transport 
[20]. Receptor activity has been demonstrated in 
vesicular fragments derived from the membrane [2 1 ] . 
One affinity labelling analogue, p-(trimethylammo- 
nium) benzene diazonium tetrafluoroborate (XVII) 
[22], has been shown to block a receptor site [23] 
as well as at least two classes of sites on the enzyme 
(the anionic site of the active centre and a second 
non-catalytic anionic site) [24-261 . Several alkylating 
inhibitors have been synthesized: bromoacetylcholine 
bromide (XVIII), p-nitrophenyl ester of p-carboxy- 
phenyltrimethylammonium iodide (XIX) [27] and 
4-(N-maleimide)-phenyltrimethylammonium iodide 
(XX) [28,29] . These reagents had virtually no irre- 
versible effects unless the tissue was treated with a 
reducing agent prior to their addition. Their non- 
specific counterparts, e.g., bromoacetate or NEM, 
were much less effective as inhibitors [29] . Recent 
studies showed that the amount of alkylating reagent 
incorporated into the tissue greatly exceeded the es- 
timated number of receptor sites [29]. 
2.7. Noradrenaline &receptor 
This drug receptor has been extensively studied 
in the rat vas deferens [31, 321. N-(2-Bromoethyl) 
N-ethyl-1-naphthylamine (XXIII), a competitive anta- 
gonist of noradrenaline known to form covalent 
bonds with tissue proteins was adsorbed in large 
quantities, and showed little specificity for the (Y- 
receptor. Prior treatment of tissue with a reversible 
antagonist did not result in a detectable decrease in 
amount of inhibitor taken up by the tissues. Experi- 
ments with a variety of amino compounds showed 
no correlation between their protective effects and 
their sympathomimetic activities. It was concluded 
that the tissue had a high binding capacity for the 
2-halogenoethylamines and that these were largely 
unrelated to specific receptor sites. 
2.8. Estrogen receptor of rat uterus 
4-Mercuri-17-/3-estradiol (XXV), a competitive 
inhibitor of 17$estradiol (XXIV) [33] , showed 
estrogen activity in rat uterus tissue preparations 
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Enzyme Labelling reagent Comments 
Adenosine triphos- 
phatase, sarcoplasmic 
reticulum 
Acetylcholinesterase, 
human red cell 
Table 3 
Labelling of membrane-associated nzymes. 
Amount of radioactivity incorporated into membrane 
preparation decreased in proportion to amount of ATP 
used for protection. Between 1 and 8 sulphydryl groups 
protectable, depending of ATP concentration. When 
1 SH group protected per 10’ g protein, most of radio- 
activity confined to 1 band, corresponding to major pro- 
tein band. Total number of counts with protection was 
40% that without protection. No direct evidence that 
labelled band corresponded to ATPase. 
Enzyme highly purified and crystallized before labelling. 
Inhibitor blocks anionic site of active centre plus non- 
catalytic auionic site. 
Label is predominantly in single band with MW = 90,000 
daltons in SDS-acrylamide. In presence of substrate, 
amount of labelling reduced by 80%. 
[34] which was prevented by prior treatment with 
sulphydryl reagents. Binding of the mercurial to 
soluble proteins from uterine tissue was inhibited 
by unlabelled 17-fl-estradiol. The concentration of 
the mercurial required for maximal stimulation of 
induced enzyme activities was five times as high as 
that of the 17-/3-estradiol; the reason for this differ- 
ence is not known. 
2.9. Antigen receptors 
Two studies have recently been made of labelling 
of cell-bound antigen receptors [36,37] but the 
results are too preliminary for final assessment. 
2.10. Membrane-bound enzymes 
Two other membrane enzymes have been labelled 
(table 3). 
2.11. Miscellaneous techniques and reagents 
Several physical techniques have recently been 
used to study other aspects of membrane structure 
or function (table 4). They require the use of reagents 
which are designed to localize in different areas with- 
in the membrane by virtue of the chemical proper- 
ties of the non-probe portion of the molecule [43- 
Refs 
38 
-- 
22,23 
39 
491. In addition, substrate analogues may be syn- 
thesised which incorporate either a fluorescent probe, 
a spin label radical, or a function suitable for nuclear 
magnetic resonance studies. Such reagents will pro- 
bably be more useful in studies on isolated trans- 
porter or receptor proteins in model membrane systems, 
than on the intact biological membranes. 
2.12. General comments on in situ labelling 
In each of the above examples the Iabelling was 
found to be more or less non-specific. It is ironic that 
the labelling of the lactose permease, with NEM, was 
at least as specific as that of any of the other systems. 
This raises the question of whether it is worth the 
effort to synthesize substrate analogues, although 
it is true that in some cases non-specific inhibitors 
are relatively ineffective. On the other hand, since 
the purpose of labelling is only to identify a particular 
protein, a moderate amount of non-specific labelling 
might be acceptable, provided that it is distributed 
randomly in contrast to the specific labelling which 
ought to be in a single protein. 
They are probably a variety of reasons for the non- 
specific labelling. One of these is that the majority of 
potentially reactive amino acid side chains do not be- 
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Membrane function 
or location 
Membrane proteins 
whose amino acid side 
chains are exposed 
to internal or bulk 
phase solvent 
Mobility and 
chemical environment 
of membrane lipids an 
proteins 
Mobility and orien- 
tation of membrane 
lipids and proteins 
May 1971 
Table 4 
Other reagents and techniques for studying membranes. 
Reagent Comments 
4-Acetamido-4’-isothiocyanostilbene-2,2’- 
disulphonic acid (XxX1). 
Non-pentrating. Binds to protein. Reacts 
completely after 5 min, with maximum uptake 
of about 5 X 10’ moles per red cell. Labelled 
residues not identified. 
7-Diazonium-1,3-napthylene-disulphonate 
(XXXII). 
Non-penetrating, fluorescent. Used to demon- 
strate the sulphate binding protein is accessible 
to solvent. Inhibits sulphate binding, sulphate 
transport and p-galactoside transport. 
Naphthalene-ldiazonium-4~sulphonate 
(XXXIII). 
Non-penetrating and fluorescent. Will be 
used to determine whether any protein 
species are accessible from both inside and 
outside of membrane. 
Measurements of fluorescence quanta yields 
and emission spectra for probe in liposomes 
compared with known solvent mixtures pro- 
vides information on proximity, rotational 
mobility and polarity of probe, and of its 
environment within membrane. Fluorescent 
substrate analogues also can be synthesized. 
12-(9-Anthroyl)-stearic acid (XXXIV), 
Ndansyl-phosphatidylethanolamine (XXXV), 
and N-octadecyl-naphthyl-2-amine-6-sulpho- 
nate (XXXVI) localize in the hydrocarbon, 
glycerol, and aqueous interfacial regions, 
respectively. 
The 4’,4’dimethyloxazolidine nitroxide 
of methyl stearate (XXXVII), or cholestane 
nitroxide incorporated into phospholipid spheru- 
les and relaxation rates of nitroxide label mea- 
sured by paramagnetic resonance. Nitroxide 
radical may theoretically be incorporated into 
substrate analogues, for study of transport proces 
Refs 
40 
41 
42 
43 
44-48 
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Table 4 (continued) 
Membrane function 
or location 
Reagent Comments Refs 
Interaction between 
membrane proteins 
and small molecules. 
Proton magnetic resonance or 
t9F magnetic resonance 
Interaction of adrenaline with adipose cell 
membrane studied by measuring relaxation 
of drug protons. Membrane protons not 
distinguishable. 
49 
long to the protein to be labelled. Although the affi- 
nity between the specific reagents and the transporter 
or receptor binding site should increase the rate and 
possibly the extent of labelling at this site compared 
with other sites, the odds against this in most cases 
may simply be too high. In systems such as the dicar- 
boxylate transporter, the relatively high K, makes 
the situation even more unfavourable. Another point 
is that in some cases there are several proteins with an 
affinity for a particular ligand and each of these may 
be labelled. For example, in rat liver inner mitochon- 
drial membranes, there are several carriers and at least 
one enzyme (succinate dehydrogenase) with binding 
sites for dicarboxylate anions. Finally, the possibility 
should be kept in mind that membrane proteins may 
be intimately linked, structurally and functionally, 
to one another in such a way that inhibition of one 
species in the membrane may be reflected in the acti- 
vities of the other species as well. Although Changeux 
and colleagues [20] have proposed that cooperative 
effects may be involved in certain normal membrane 
functions, there is little experimental evidence in 
support of this possibility. However, in the case of 
the soluble complex of phosphorylase a and alanine 
aminotransferase from rabbit muscle, competitive 
inhibitors of one enzyme have a marked inhibitory 
effect on the activity of the other member of the 
complex, whereas these ‘crossed’ effects are not seen 
when the isolated enzymes are tested with the same 
inhibitors [50] . Thus it may be necessary to isolate 
the labelled component(s) and characterize them 
with respect to structure and/or function before eva- 
luating the specificity of the labelling. 
Because of the technical difficulties usually en- 
countered in purifying membrane proteins, the 
fastest way of estimating the number of labelled com- 
ponents may be to do a preliminary fractionation of 
the solubilized proteins, and then subject the labelled 
fraction to enzymatic digestion, high voltage electro 
phoresis, and radio-autography. Specific labelling 
will be indicated by one or a small number of major 
peptides with a unique amino acid sequence, where- 
as a non-specific reaction will result in a large number 
of minor peptides. 
There are several possible ways to increase the 
specificity of labelling: 
a) Substrate protection: Although this was effec- 
tive for the lactose pennease, it has not been very 
successful for most of the other membrane systems. 
b) Photoactivated affinity labels: These reagents 
are useful in situations where there is a sufficiently 
high affinity between ligand and binding site to allow 
non-specifically adsorbed label to be removed before 
the inhibitor is activated. The type of reagents pre- 
sently available are diazoketones [51] and aryl azides 
[52]. A possible advantage of the latter compounds 
is that they are activated at wavelengths greater than 
400 nm and may have less effects upon aromatic 
amino acids and other cellular constituents. These 
reagents have not yet been used for cellular or mem- 
brane systems. 
c) Optimizing incubation conditions: Specific label- 
ling will be favoured by the use of a low molar ratio 
of inhibitor to active site, and short duration of incu- 
bation. Although these conditions are likely to give 
less than 100% inhibition and a corresponding reduc- 
tion in number of sites labelled, this may be relatively 
unimportant in return for the increased specificity. 
A final difficulty inherent in affinity labelling is 
that it usually, although not invariably, inactivates 
the labelled protein. This makes it difficult to study 
the biological activity of the isolated protein and 
to use it in reconstitution experiments. It is some- 
times possible to reactivate inhibited proteins, for 
example, deacylation of serine hydroxyl residues in 
certain proteases [ 531 and thiolytic cleavage of dini- 
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trophenyl residues [54, 551, but it is not certain that 
this will be feasible with all labelling reagents or all 
proteins. 
In conclusion, we feel that the usefulness of aff- 
nity labelling in the isolation of membrane proteins 
has yet to be proved. Furthermore, the technical dif- 
ficulties and inherent shortcomings are sufficiently 
great to warrant the use of supplementary or alterna- 
tive approaches. The remainder of this review is de- 
voted to consideration of one such approach. 
3. Solubilization of membrane followed by purifi- 
cation 
The use of osmotic shock in bacteria has resulted 
in isolation of large and growing family of proteins 
which have specific high affinity binding sites (usual- 
ly one per protein) for transported molecules such 
as galactose and amino acids [56, 571. There is a 
great deal of indirect evidence implicating the binding 
proteins in bacterial membrane transport. This evi- 
dence was carefully evaluated by Kaback [57] who 
concluded that whilst these proteins may in some 
cases be necessary for transport, there is no evidence 
that they are sufficient. 
Osmotic shcok has recently been used by Lehnin- 
ger’s group in an attempt to solubilize the energy- 
dependent Ca2+ transport system which they have 
described in rat liver mitochondria [ 58,591. The 
preliminary results with the mitochondrial system are 
very reminiscent of those with bacterial binding pro- 
teins, and we think that the reservations presented by 
Kaback [ 571 apply to the mitochondrial systems. 
It is likely that there are other proteins involved in 
transport which are intimately bound within mem- 
branes and which have not yet been obtained in 
soluble, active form. Examples of such proteins are 
the M protein of the lactose operon [7], and the 
family of Enzymes II in the phosphoenolpyruvate- 
dependent phosphotransferase system [60]. A third 
example of this type of protein may be the choliner- 
gic receptor of the electroplax, which has recently 
been solubilized using 1% deoxycholate [61]. The 
solubilized receptor activity and that seen in isolated 
electroplax membrane or vesicular membrane frag- 
ments [21] are very similar to one another with 
respect to the dissociation constants for several ago- 
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nists and antagonists, and the irreversible inhibition 
by o-bungarotoxin [62]. In addition, the receptor 
activity and the catalytic activity due to acetyl- 
cholinesterase appear to be on separable proteins, as 
indicated by ultracentrifugation and selective heat 
denaturation [62] . 
An inherent difficulty with this approach is that 
most of the activities associated with membranes 
cannot be assayed once the membrane has been dis- 
rupted. The solubilized proteins can be tested only 
for the ability to bind substrates or inhibitors. Even 
when the various kinetic properties of the soluble 
and membrane activities coincide, it is difficult to 
unequivocally relate this binding to the biological 
activity in question. Some uncertainty must remain 
until the protein can be shown to mediate the acti- 
vity itself. 
The types of binding assays (equilibrium dialysis, 
ion exchange, etc.) used for high affinity systems are 
not likely to be useful for systems with affinities of 
the order of 10m3 M. For this reason, we are pre- 
paring affinity chromatographic reagents which can 
be coupled with the amino-analogues of dicarboxyl- 
ate anions for the assay and purification of the mito- 
chondrial dicarboxylate transporter. This technique 
is especially promising because it has been used 
successfully to purify fl-galactosidase using a relative- 
ly weak competitive inhibitor, p-aminophenyl&D- 
thiogalactopyranoside, Kj about lob3 M [63,64] . 
The principles of affinity chromatography have been 
discussed by others [64-661. It appears that the 
optimal linkage for a given protein-ligand system 
can be determined only by trial and error, although 
it has been suggested that the length and possibly 
the nature of the hydrocarbon chain between the 
insoluble matrix and the ligand is especially critical 
for weakly binding systems [64] . The major problem 
with this approach (apart from the detection and 
identification of a small amount of specifically bound 
protein) is the solubilization of the membrane. The 
technique as usually carried out requires biologically 
active proteins in aqueous solution. Therefore, most 
of the techniques used for solubilizing membranes, 
which denature the proteins, cannot be used. On the 
other hand, less drastic techniques may not be ade- 
quate for solubilizing transport proteins, and tech- 
niques may have to be developed for the extraction, 
purification and assay of these proteins in a hydro- 
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Table 5 
Techniques used for isolation of membrane proteins. 
Protein and source Comments 
May 1971 
Refs 
Sonication 
Osmotic shock 
Distilled water 
Low ionic strength ATPase, Str. faecalis 
High ionic strength 
Chelating agents 
Extraction of acetone 
powder with neutral or 
alkaline aqueous buffers 
Lubrol ATPase, brain microsomes 
Triton X-100 Acetylcholinesterase, 
electroplax electric organ 
Deoxycholate 
Alkaline borohydride 
Enzyme digestion 
Coupling factor Fo 
(oligomycin-sensitivity conferring 
factor), beef heart mitochondria 
High affinity binding proteins, 
Gram negative bacteria 
‘Structural’ protein from 
human red cell ghosts 
Protein from human red cell 0.8 M NaCl solubilizes about 40% 
ghosts of membrane protein. 
‘Spectrin’, human red cell 5 mM EDTA, low ionic strength 
ghosts buffer, plus &mercaptoethanol. 
Succinate dehydrogenase, beef 
heart mitochondria 
ACh receptor, electroplax 
electric organ 
Polypeptide with 
phytohaemagglutinin receptor 
activity, human red cell ghosts 
Protein with sucrase-isomaltase 
activity, plus carrier-like sugar 
binding site, hamster small 
intestine 
isolated from submitochondrial 
particles previously treated with 
trypsin, EDTA, and urea. Particulate. 
Proteins released are probably peri- 
cytoplasmic or loosely bound to mem- 
brane rather than integral components 
of membrane. 
Membrane completely solubilized 
only if ghosts have been thoroughly 
deionized. 
Enzyme solubilized by repeated 
washes with 1 mM tris HCl buffer 
in absence of Mg’+. 
Enzyme isolated in presence of succinate 
(or certain reducing agents) retains 
activity in succinate oxidase (respiratory 
chain) and phenazine methosulphate 
assays, whilst in absence of substrate, 
only latter activity retained. Mechanism 
of substrate ffect not known. 
Large amount of lubrol adheres to 
solubilized proteins. 
0.5% w/w detergent solution for 
48 hr at 4”. Sonication prior to 
detergent reatment. Enzyme 
partially inactivated. 
1% w/w detergent solution. 
Acetylcholinesterase also solubilized. 
Multiple enzyme digestions also 
required. 
Trypsin, in presence of 5 M urea 
also used. 
70 
56 
69 
71 
67 
68 
72 
19 
73 
61 
74 
75 
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Table 6 
Organic solvents for solubilizing membranes. 
Solvent 
Acetic acid 
Comments 
80% aqueous solution gives almost complete solubilization of red 
cell membrane. 
Refs 
77 
ZChloroethanol, ethylcellosolve, 
methylcellosolve, formamide, 
dimethylformamide, diethylene 
glycol monobutyl ether 
Pyridine 
9:l v/v solvent: water, pH brought to 2 with HCl; solubilization of 
95% of membrane protein; all solvents miscible with water; interact 
with hydrogen bonds, and have high lipid solubility; proteins retain 
some secondary structure, but effect upon biologic activity is unknown. 
33% aqueous pyridine dissolves red cell membranes; proteins tend 
to aggregate ven in presence of pmercaptoethanol. 
77-79 
80 
Butanol 
Urea or guanidine 
See text. 
Produce random polypeptide chains if disulphide bonds have 
been reduced and alkylated; most proteins denatured, but in 
some cases, reversibly. 
76 
67,81 
Sodium dodecyl sulphate SDS binds to all proteins in constant proportion w/w: 0.4 and 1.4 g 
SDS/g protein at SDS monomer concentrations of 5-8 X 10e4 M, 
and>8X lo4 M respectively; polypeptide chains not completely 
random. 
82 
Use of SDS resulted in isolation of low molecular weight proteins 
(6500-10,000 daltons), in yields of 30-90% of total protein, from 
red cells, mitochondria, retinal rods, and sarcoplasmic reticulum. 
83,84 
phobic environment. This problem will be discussed 
in the foal section. 
3.1. Solubilization of membrane proteins 
There are two broad approaches to this problem. 
The first involves the application of techniques used 
for aqueous systems. It is clear that a variable, and 
sometimes large, amount of protein can be solubilized 
using fairly mild conditions, such as high ionic strength 
[67], chelating agents [68] and even distilled water 
[69] . We have shown that large amounts of protein 
can be solubilized from rat liver mitochondria using 
either 0.8 M NaCl or 1 mM EDTA [ 1 l] . These tech- 
niques may be even more valuable when combined 
with additional physical or chemical techniques. Note 
that in most of the examples listed in table 5, several 
techniques have been used sequentially. 
Many membrane proteins are difficult to solubilize 
under these conditions [7] , others tend to aggregate 
irreversibly [67], and still others are unstable in 
aqueous solutions [76]. Furthermore, these difficul- 
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ties may occur even in the presence of detergents and 
other denaturing reagents [67] . Nevertheless, solu- 
bilization and fractionation may be considerably 
facilitated by the use of reagents such as ionic deter- 
gents, urea, guanidine, and organic solvents (table 6). 
We have been able to separate solubilized mitochondrial 
proteins into 5 or 6 major fractions using anion ex- 
change chromatography with 8 M urea and a linear 
salt gradient [ 1 l] . Under these conditions, most pro- 
teins will undergo irreversible denaturation, and con- 
sequently the usefulness of this technique for our 
purposes is limited. 
The recent work of Strominger’s group has indi- 
cated the possibility of extracting membrane proteins 
directly into organic solvents without denaturation 
[76] . In principle this is a very sensible way of 
handling such proteins, although it may not always 
be successful [7]. Strominger’s results will be given 
in some detail because of the interest and novelty of 
the approach. The enzyme, an ATP-dependent C-55 
isoprenoid alcohol phosphokinase from the membrane 
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of Staphylococcus aureus, has the following proper- 
ties: 1) extractable in active form into acidic butanol 
at room temperature, from which it precipitates re- 
versibly at - 15” ; 2) stable in organic solvents such 
as acetone, heptane, ether and benzene, but not chloro- 
form-methanol (1: 1); 3) insoluble in water and rela- 
tively unstable in aqueous buffers; 4) undergoes 50% 
increase in activity upon heating in butanol at 100’ 
for 20 min; 5) enzyme activity requires either phos- 
phatidyl glycerol and/or cardiolipin, but this require- 
ment may be partially satisfied by certain detergents 
[76,85]. 
It will be necessary to screen a variety of such or- 
ganic solvents in order to assess the general usefulness 
of this approach. Proteins solubilized in this way can 
be fractionated in ways analogous to those used for 
lipids and other non-polar molecules. This requires 
the development of hydrophobic derivatives of dex- 
tran or acrylamide beads and other supporting mate- 
rials [86] , such as Sephadex LH 20. The feasibility 
of detecting reactions which are largely ionic or electro- 
static in non-polar solvents is uncertain, although such 
reactions are known to occur [87]. It may be possible 
to synthesize affinity columns which can be used in 
non-polar systems. 
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